Novus Therapeutics Innovative (ENT) Therapies


Novus Therapeutics is a development stage pharmaceutical company focused on the development of products for disorders of the ear, nose, and throat (ENT).  Novus has two technologies, each of which has the potential to be developed for multiple ENT indications.  The company’s lead product (OP-02) is a surfactant-based, combination drug product being developed as a potential first-in-class treatment option for patients at risk for or with otitis media (“OM”) (middle ear inflammation with or without infection), which is often caused by Eustachian tube dysfunction (“ETD”).  Globally, OM affects more than 700 million adults and children every year.  OM is a common disorder seen in pediatric practice, and in the United States is the most frequent reason children are prescribed antibiotics and undergo surgery.  Novus also has a foam-based drug delivery technology (OP-01), which may be developed in the future for delivery of drugs into the ear, nose, and sinus cavities.

Read More

Explore Novus Therapeutics


icon5

OP-02 Surfactant Program

OP-02 is a surfactant-based, combination drug product being developed as a potential first-in-class treatment option for patients at risk for or with otitis media.
icon3

About Novus

Passionate people driven by a common vision to solve unmet clinical needs for patients in an underserved therapeutic area
icon6

Company News & Events

Keep up on the latest public announcements, clinical activities, and company conference participations
icon3

Contact Us

Do you need more information or wish to contact one of our team members?